Search Results for: "Clinic Roundup"
-
Clinic Roundup
Provectus Pharmaceuticals Inc., of Knoxville, Tenn., reported top-line data for its Phase II trial of PH-10 in mild to moderate plaque psoriasisBioWorld Today | Tuesday, March 20, 2012 -
Clinic Roundup
Gilead, which reported top-line data from Study 102 in August 2011, submitted a new drug application for Quad late last year. (See BioWorld Today, Aug. 16, 2011BioWorld Today | Friday, March 9, 2012 -
Clinic Roundup
Top-line data are expected in the third quarter...Top-line data are expected in the third quarterBioWorld Today | Monday, March 5, 2012 -
Clinic Roundup
Assuming its clinical trial application is granted, top-line data would be available in the third quarter, with a Phase II data in DMD patients starting in the first half of 2013BioWorld Today | Wednesday, February 15, 2012 -
Clinic Roundup
Zealand Pharma A/S, of Copenhagen, Denmark, said partner Sanofi SA, of Paris, disclosed top-line data from the GetGoal-P Phase III study, showing lixisenatide, a once-daily glucagon-like peptide 1 agonist, hit its primary efficacy endpoint of significantly reducing blood glucose levels compared to placebo (p < 0.0001), with HbA1c decreasing from a mean baseline value of 8.08 percent to a mean value of 7.06 percent after 24 weeks in the lixisenatide group and from 8.05 percent to 7.59 percent inBioWorld Today | Thursday, February 9, 2012 -
Clinic Roundup
The company expects to complete the Phase III and release top-line data in mid-2012BioWorld Today | Tuesday, January 31, 2012 -
Clinic Roundup
Infinity has completed enrollment in the Phase II portion of the study, with top-line data anticipated in the second half of this yearBioWorld Today | Monday, January 23, 2012 -
Clinic Roundup
The company previously reported top-line data showing that combining its investigational purine nucleoside phosphorylate inhibitor, BCX4208, with a 300-mg dose of allopurinol could double the number of patients who achieve normal sUA levels. (See BioWorld Today, Oct. 6, 2011BioWorld Today | Tuesday, January 10, 2012 -
Clinic Roundup
Civitas Therapeutics Inc., of Chelsea, Mass., reported top-line data from a Phase I healthy volunteer trial of CVT-301, an inhaled formulation of levodopa (L-dopa) in development for the rapid relief from motor fluctuations associated with Parkinson's disease...Durect Corp., of Cupertino, Calif., said top-line data from its Phase III BESST (Bupivacaine Effectiveness and Safety in SABER) study of Posidur in postoperative pain relief failed to reach statistical significance, though results trendedBioWorld Today | Monday, January 9, 2012 -
Clinic Roundup
Top-line data from the first Phase III study is expected around the end of 2012 and from the second Phase III in early 2013BioWorld Today | Wednesday, December 28, 2011 -
Clinic Roundup
Rib-X Pharmaceuticals Inc., of New Haven, Conn., reported top-line data from its Phase IIb study of antibiotic delafloxacin for acute bacterial skin and skin structure infections, including those caused by methicillin-resistant Staphylococcus aureus, indicating that delafloxacin met or exceeded primary and secondary efficacy endpoints when compared to Zyvox (linezolid, Pfizer Inc.), with and without aztreonam, and vancomycin, with and without aztreonamBioWorld Today | Friday, December 16, 2011 -
Clinic Roundup
The companies expect to report top-line data during the first quarter of 2012 and to complete enrollment and report data from the second Phase III, ULISES 008, during the first half of next yearBioWorld Today | Friday, December 9, 2011 -
Clinic Roundup
ViroPharma Inc., of Exton, Pa., and Halozyme Therapeutics Inc., of San Diego, reported top-line data from an open-label Phase II trial of a subcutaneous version of hereditary angioedema drug Cinryze (C1 esterase inhibitor), showing that the addition of Halozyme's Enhanze delivery technology, which uses recombinant human hyaluronidase enzyme, led to maximum levels and greater systemic exposure of functional and antigenic C1 inhibitor for both doses tested as compared to subcutaneousBioWorld Today | Wednesday, December 7, 2011 -
Clinic Roundup
Top-line data showed that, at the end of the open-label phase, mean daily "off time" was reduced from baseline by 2.0 hours for Sinemet compared to 3.4 hours for 279/CDBioWorld Today | Tuesday, December 6, 2011 -
Clinic Roundup
Top-line data are anticipated in the first half of 2013BioWorld Today | Friday, December 2, 2011 -
Clinic Roundup
Top-line data are anticipated in April 2012BioWorld Today | Wednesday, November 30, 2011 -
Clinic Roundup
Top-line data are expected by late 2012BioWorld Today | Tuesday, November 29, 2011 -
Clinic Roundup
GlaxoSmithKline plc, of London, said top-line data from the first of eight Phase III studies of albiglutide, a once-weekly glucagon-like peptide-1 agonist, failed to meet the primary endpoint of noninferiority to Victoza (liraglutide, Novo Nordisk A/S), though it did demonstrate a statistically significant reduction in HbA1c from baseline (p < 0.001...Nile Therapeutics Inc., of San Mateo, Calif., released top-line data from a Phase I trial of cenderitide in chronic heart failureBioWorld Today | Thursday, November 17, 2011 -
Clinic Roundup
Top-line data from the RESTORE-CLI study were reported last year. (See BioWorld Today, Nov. 19, 2010BioWorld Today | Tuesday, November 15, 2011 -
Clinic Roundup
The second Phase III trial is expected to complete enrollment by the end of the year, with top-line data from the first trial anticipated around the end of 2012BioWorld Today | Friday, November 11, 2011
Category
BioWorld | 3525 Piedmont Road
Building 6, Suite 400 | Atlanta, Georgia 30305, USA
Building 6, Suite 400 | Atlanta, Georgia 30305, USA
Part of Thompson Media Group LLC
Free Ezine
Sign up for Perspectives FREE e-mail newsletter.
Customer Service: In the U.S. and Canada: 1-800-477-6307
Outside the U.S.: 1-404-262-5476
customerservice@bioworld.com
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST
Outside the U.S.: 1-404-262-5476
customerservice@bioworld.com
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST
Copyright @ 2013 AHC Media. Reproduction, reposting content is strictly prohibited.